MedTrace Logo

Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain

NCT03959852 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-09-11

No results posted yet for this study

Summary

The objective of this study is to evaluate the potential opioid-sparing effect associated with the novel combination of fentanyl and sub-dissociative ketamine in adult patients with moderate to severe pain in the emergency department.

Conditions

  • Pain, Acute

Interventions

DRUG

Fentanyl

1 mg/kg of Fentanyl IV administered over at least 1 minute

COMBINATION_PRODUCT

Fentanyl and Ketamine

Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.

DRUG

Ketamine

0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute

Sponsors & Collaborators

  • Mercy Health Ohio

    lead OTHER

Principal Investigators

  • David Gemmel · Director of Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2020-06-05
Completion
2020-06-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03959852 on ClinicalTrials.gov